RxDoctor Payments Data

Mahammed Saiyed, MD

Family Medicine · Windsor, CTNPI 1326253469

Payments from drug & device makers

$381in general payments, 2019–2025

Across 20 payments — averaging $19.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$78
  • GSK$50
  • Pfizer$49
  • Genentech USA, Inc.$39
  • Lilly USA, LLC$39
  • AbbVie$26
  • plus $100 from 5 others

What the payments were for

  • Food & beverage$381100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk4$78
GSK2$50
Pfizer3$49
Genentech USA, Inc.2$39
Lilly USA, LLC2$39
AbbVie(2 entities)2$26
Novartis1$24
Amgen1$23
Dexcom, Inc.1$21
Kyowa Kirin, Inc.1$19
AstraZeneca1$13

How this compares

$381 in reported general payments places this provider in the 55th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$52,212
Medicare patients
179
Services billed
547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide24$54,966
JanuviaSitagliptin Phosphate31$40,760
EliquisApixaban43$39,522
JardianceEmpagliflozin26$39,389
OzempicSemaglutide27$35,970
TradjentaLinagliptin31$29,077
JanumetSitagliptin Phos/Metformin Hcl18$27,360
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,184
Tresiba Flextouch U-200Insulin Degludec18$15,857
EntrestoSacubitril/Valsartan14$12,634
Breo ElliptaFluticasone/Vilanterol13$10,161
Tresiba Flextouch U-100Insulin Degludec19$10,041
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$7,132
Potassium Chloride42$5,492
Levothyroxine Sodium347$3,600

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$78$90,93651 claims
PfizerEliquis$49$39,52243 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$50$34,47754 claims
NovartisEntresto$24$12,63414 claims
AbbVieSynthroid$26$2,30342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Windsor

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →